# An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

> **NCT04206813** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Boston Medical Center** · enrollment: 352 (actual)

## Conditions studied

- HPV Infection

## Interventions

- **DRUG:** Gardasil 9 2 dose regimen
- **DRUG:** Gardasil 9 3 dose regimen
- **DRUG:** Gardasil 9 rescue dose

## Key facts

- **NCT ID:** NCT04206813
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-01
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-10
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04206813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04206813, "An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04206813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*